Dyno Therapeutics
1 Kendall Square
Building 1400E, Suite 202
Cambridge
MA
02139
United States
Website: https://www.dynotx.com/
6 articles with Dyno Therapeutics
-
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
From the continuing fight against COVID-19 to new companies emerging in exciting therapeutic areas to the people who mattered most, here’s a look at just some of the biggest successes, most dramatic flops – and a few that fall somewhere in between.
-
With this new collaboration, Astellas will take advantage of Dynos' next-gen AAV vectors to deliver its gene therapy.
-
Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle
12/1/2021
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Dyno Therapeutics, Inc. (President and CEO: Eric Kelsic, Ph.D., "Dyno") today announced an option and license agreement was signed on November 23 to develop next-generation adeno-associated virus (AAV) vectors for gene therapy directed to skeletal and cardiac muscle using Dyno's CapsidMap™ platform.
-
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
-
Since emerging from stealth mode in 2020 Dyno Therapeutics has been busy advancing its gene therapy platform. This morning, the company bolsters its research with $100 million raised in a Series A financing round.